Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Reviews on Recent Clinical Trials|June 3, 2014
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus InfectionIvan Gentile, Antonio R Buonomo, Guglielmo Borgia
Current Medicinal Chemistry|July 16, 2013
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvirI Gentile, F Borgia, A R Buonomo, et al.
Annali Dell'Istituto Superiore Di Sanita|January 1, 1992
Interactive patterns in the schizophrenic family during hospitalizationP Preziosa, R Buonomo, A Busnelli, et al.
Current Medicinal Chemistry|December 31, 2013
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5AI Gentile, F Borgia, N Coppola, et al.
Plant Biology (Stuttgart, Germany)|July 30, 2013
Soilless cultivation of soybean for Bioregenerative Life-Support Systems: a literature review and the experience of the MELiSSA Project - Food characterisation Phase IR Paradiso, V De Micco, R Buonomo, et al.
Infection|January 26, 2020
Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experienceA R Buonomo, A E Maraolo, R Scotto, et al.
Expert Opinion on Drug Safety|April 21, 2021
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive reviewR Scotto, A Reia, A R Buonomo, et al.
Idcases|November 25, 2024
Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM)A R Buonomo, L Cattaneo, G Viceconte, et al.
Diabetes Research and Clinical Practice|March 6, 2022
Diabetes and COVID-19: The potential role of mTORB Pinchera, R Scotto, A R Buonomo, et al.
Annals of Medicine|December 11, 2024
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre studyI Gentile, G Viceconte, F Cuccurullo, et al.
Pageof 1